MAMMALIAN Rho-GTPases comprise a family of over 20 signaling molecules that are often referred to as molecular switches (14) because they cycle between active (GTP bound) and inactive (GDP bound) states. They are best characterized for their roles in the organization of the actin cytoskeleton, thereby mediating fundamental processes such as cell adhesion, migration, and proliferation (10) . RhoA, Rac1, and Cdc42 are the prototypical members (31) that control the formation of stress fibers, lamellipodia, and filopodia, respectively (8) . RhoGTPases are under tight regulatory control by three groups of molecules. Guanine nucleotide exchange factors activate RhoGTPases in response to various stimuli by facilitating the exchange of GDP for GTP (26) . Rho-GTPase-activating proteins hydrolyze GTP to GDP, thereby enhancing the otherwise slow intrinsic GTPase activity of Rho-GTPases, leading to their inactivation (35) . Guanine nucleotide dissociation inhibitors (GDIs) bind and sequester inactive Rho-GTPases in the cytosol and prevent nucleotide exchange. We have recently reported two siblings with nephrotic syndrome (NS) caused by a homozygous 3-bp deletion in the gene ARHGDIA, which encodes for Rho-GDI␣ (GDI␣) (13) . Subsequently, two other families have been reported with homozygous mutations in ARHGDIA and NS (11) . All three mutations result in a loss of function (11, 13) . Thus, it is presumed that loss of function of GDI␣ with resulting Rho-GTPase hyperactivation in podocytes is the cause of NS. Consistent with these clinical findings, GDI␣ knockout mice show heavy proteinuria and die of kidney failure within a year (36) .
The signature morphological change of injured podocytes in NS is the loss of the intricate tertiary processes called foot processes. In addition, a number of molecular and metabolic changes can occur in injured podocytes, such as the activation of tyrosine or serine/threonine kinases, production of ROS, increase in intracellular Ca 2ϩ concentration, and increase in endoplasmic reticulum stress (24) . Activation of p38 MAPK has been documented in a number of podocyte injury models (18, 33) . For example, podocyte injury by mechanical stretch has been shown to activate p38 signaling. In this setting, p38-dependent imbalances in PGE 2 signaling occurred, contributing to podocyte injury (22) . Activation of p38 in podocytes has been observed in human kidney biopsies from patients with minimal change disease and focal segmental glomerulosclerosis (FSGS) (33) and in rodent models where a specific inhibitor of p38 was protective against podocyte injury (18, 25) . Thus, p38 activation is an established marker of podocyte injury.
Synaptopodin is a proline-rich, actin-binding protein of ϳ100 kDa that is expressed within the kidney exclusively in podocytes (6) . In podocytes, synaptopodin binds to and stabilizes filamentous actin (3), prevents aberrant filopodia formation (40) , and plays an important role in cell migration (3) . Synaptopodin loss has been documented in a number of podocyte injury models both in vitro (45) and in vivo (9) . Synaptopodin-deficient mice show impaired recovery from protamine sulfate-induced foot process effacement and LPS-induced proteinuria (2) , and bigenic heterozygous knockout mice for synaptopodin and CD2-associated protein (CD2AP) show spontaneous proteinuria and FSGS-like glomerular changes (16) . Thus, synaptopodin loss is an important contributor to podocyte injury. While the protease cathepsin L has been reported to contribute to LPS-induced synaptopodin degradation, only a partial rescue of synaptopodin was observed when podocytes were treated with an inhibitor to cathepsin L, suggesting that additional mechanisms are involved (9) . The ubiquitin-proteasome system is known to regulate the turnover of numerous proteins (7, 21, 41) . However, it is not known if synaptopodin degradation is regulated by the ubiquitin-proteasome system.
The onset of NS associated with GDI␣ mutations ranges from 1 mo to 2 yr of age (11, 13) . While the variable time of onset could reflect the severity of mutations, environmental injury, in addition to genetic derangement, may influence the severity of the podocyte damage and onset of NS. An analogous example has been reported in the CD2AP knockout mouse, in which actin cytoskeletal derangements sensitized podocytes to transforming growth factor-␤ 1 injury (38) . In the present study, we characterized podocytes deficient in GDI␣. We hypothesized that loss of GDI␣ in podocytes would confer sensitivity to injurious stimuli. We chose LPS as an injurious stimulus since it induces podocyte injury in vitro and in vivo (4, 32) and is known to activate the three prototypical RhoGTPases (RhoA, Rac1, and Cdc42) (28, 29) as well as p38 (15, 34) . In response to LPS injury, GDI␣-deficient podocytes show enhanced p38 MAPK activation via Rac1 hyperactivation, and this was not rescued by the disease-causing mutant of GDI␣, ⌬D185. In the present study, we demonstrate that GDI␣ knockdown (KD) promoted podocyte proliferation but hindered cell spreading. Finally, we show that activation of p38 MAPK contributes to synaptopodin degradation via the previously unrecognized ubiquitin-proteasome pathway, which is augmented in GDI␣-deficient and ⌬D185 mutant-expressing podocytes.
METHODS

Reagents.
Tissue culture reagents, including RPMI-1640, PBS, FBS, trypsin/EDTA, G418, and penicillin-streptomycin were from Wisent. LPS from Escherichia coli 0111:B4, E-64, and ML-141 as well as N-ethylmaleimide (NEM) for immunoprecipitation experiments and MTT were from Sigma-Aldrich. SB-203580, rabbit antiphosphorylated (p-)p38 antibody, and anti-rabbit IgG Alexa fluor 488 were from Cell Signalling. MG-132 was from Cayman Chemical, C3 transferase was from Cytoskeleton, and NSC-23766 was from TOC-RIS Bioscience. Rabbit anti-p38, goat anti-synaptopodin, mouse antitubulin, and mouse anti-ubiquitin antibodies as well as protein G beads were from Santa Cruz Biotechnology. Rabbit anti-synaptopodin antibody was from Abcam or Novus Biologicals, and rhodamineconjugated phalloidin was from PromoKine. Complete Mini protease inhibitor tablets were from Roche. Bradford assay dye reagent was from Bio-Rad. Aqua Mount and chemiluminescent substrate were from Thermo Scientific.
Tissue culture. All experiments were performed using conditionally immortalized murine podocytes (kindly provided by Dr. Stuart Shankland, University of Washington) cultured following the established protocol, as previously described (23) . The generation of Rho-GDI␣ KD podocyte cells [using short hairpin (sh)RNA] has also been previously described (13) . Of the 10 shRNAs tested, only 1 shRNA, which targets the 3=-untranslated region (3=-UTR) of mouse GDI␣, showed consistent KD. To minimize nonspecific effects, podocytes were transduced with shRNA-containing lentivirus and selected with puromycin, and polyclonal cells were used for experiments. Transduction was done twice, and both pools of cells showed similar results. Rescued cells were established by transfecting KD cells with green fluorescent protein (GFP)-tagged ⌬D185 or wild-type human GDI␣ (coding region alone). After selection with G418, polyclonal cells were used for experiments. Podocytes were cultured in RMPI-1640 supplemented with 10% FBS and penicillin-streptomycin and were proliferated at 33°C in the presence of interferon-␥ (permissive conditions). Cells were then thermoswitched and incubated at 37°C in the absence of interferon-␥ (nonpermissive conditions) for 7-12 days for differentiation. For all experiments, differentiated cells were washed twice with PBS and serum starved in RPMI ϩ 1% FBS overnight. Serum-starved cells were then challenged with LPS (25 g/ml) or various inhibitors for the indicated time points. The final concentrations of inhibitors used were as follows. The RhoA inhibitor C3 transferase was used at 0.1 g/l. The Cdc42 inhibitor ML-141 was used at 12.5 M. The Rac1 inhibitor NSC-23766 was used at 50 M. The protease inhibitor MG-132 was used at 12.5 M. The p38 inhibitor SB-203580 was used at 10 M. The cathepsin L inhibitor E-64 was used at 10 M.
SDS-PAGE and immunoblot analysis. Once podocytes had finished undergoing treatment, they were washed twice in ice-cold PBS and lysed in lysis buffer [1 M Tris (pH 8.0), 5 mM NaCl, 10 mM Na 4P2O7, 2 mM EDTA, 1% Nonidet P-40, and 10% glycerol] supplemented with protease inhibitors (DTT, Na3VO4, and complete protease inhibitor cocktail). Lysates were centrifuged at 13,000 rpm for 15 min at 4°C to pellet cell debris. Supernatants were then quantified by the Bradford assay. Total protein (10 g) was separated by SDS-PAGE before being transferred to nitrocellulose membranes. Membranes were blocked for 1 h in 5% BSA in Tris-buffered saline-Tween and incubated overnight with the following antibodies at their respective concentrations: anti-synaptopodin (1:4,000), antip-p38 (1:1,000), anti-p38 (1:1,000), anti-GAPDH (1:1,000), and antitubulin (1:10,000). Membranes were then incubated with the appropriate secondary antibodies (1:4,000) in 5% milk in Tris-buffered saline-Tween for 1 h. Membranes were incubated in chemiluminescence detection reagent and visualized directly with a VersaDoc imaging system (Bio-Rad) and Quantity One software.
Immunofluorescence. Cells were cultured similarly on glass coverslips coated with collagen type I (25g/ml) for 1 h. After treatment, they were washed twice with PBS and fixed with 4% paraformaldehyde for 10 min. Fixed cells were permeabilized with 0.1% Triton X-100 in PBS, blocked in 3% BSA for 30 min, and incubated with primary antibody (1:200) for 1 h or overnight. For experiments involving stress fiber evaluation, cells were stained with phalloidin without blockade. After a wash, secondary fluorescent antibody was added at a concentration of 1:1,000 for 1 h. Coverslips were then mounted with Aqua Mount, and images were captured with a Zeiss Axio-Observer microscope using AxioVision 4.8 software. Quantification of stress fibers was performed as previously described with phalloidin-stained cells and expressed as a percentage of stress fiberpositive cells (positive cells over total cells) (12) . A stress fiberpositive cell was defined as a cell with five or more transcellular fibers.
Immunoprecipitation. Differentiated control and GDI␣ KD podocytes were treated or not with MG-132 (12.5 M) for 6 h at 37°C. SB-203580 (10 M) was added 1 h before MG-132 where indicated. Cells were then lysed with lysis buffer containing NEM. Toatl protein (160 g) was added to 2 g goat anti-synaptopodin antibody in microcentrifuge tubes and rotated at 4°C for 1.5 h. Protein G beads were then added and allowed to incubate for 30 min. Pellets were washed three times in lysis buffer containing NEM. Finally, samples were mixed with 3ϫ loading buffer and separated by SDS-PAGE.
MTT assay. Control podocytes, GDI␣ KD podocytes, and KD podocytes transfected with the loss of function GDI␣ mutant (KD ϩ ⌬D185 podocytes) were seeded at a density of 2.5 ϫ 10 4 cells/well in 96-well plates with or without fibronectin coating. After 48 h, MTT solution was diluted 1:5 with complete medium such that the final concentration of MTT was 1 mg/ml. One hundred microliters of the MTT-media mixture were added to each well and incubated for 4 h at 37°C. The MTT-media mixture was then aspirated, and 100 l of acidified isopropanol were added to each well and incubated at room temperature for 15 min. The absorbance at 550 nm of each well was read in a microplate reader (ELX808, Bio-Tek Instruments) using KC Junior software (Bio-Tek).
Cell spreading assay. Differentiated control and GDI␣ KD podocytes were plated on fibronectin-coated coverslips. Cells were fixed in 4% paraformaldehyde at 30 min, 2 h, 18 h, or 24 h after plating and stained with phalloidin to visualize the F-actin cytoskeleton. Photos were captured as described above, and cell area was calculated using ImageJ software (National Institutes of Health).
Statistical analysis. All data are presented as means Ϯ SE. Data were analyzed by one-way ANOVA. P values of Ͻ0.05 were considered statistically significant.
RESULTS
Rho-GDI␣ KD sensitizes podocytes to LPS-induced p38 activation.
To determine if KD of GDI␣ in podocytes makes them more susceptible to injury, we exposed control and GDI␣ KD podocytes to LPS and determined the levels of p38 MAPK activation by immunoblot analysis for p-p38 (Fig. 1A) . When the threonine and tyrosine residues within the conserved motif Thr-Gly-Tyr are both phosphorylated, p38 is activated (Thr 180 / Tyr 182 ), and this can be detected by the phospho-specific antibody (43) . Under nontreated conditions, the level of p-p38, normalized to total p38, was significantly higher (1.87-fold increase, P Ͻ 0.05) in GDI␣ KD podocytes compared with control podocytes. After LPS treatment, p-p38 increased significantly by 15 min in both control and GDI␣ KD podocytes. At 30 min, the level continued to rise in GDI␣ KD podocytes, whereas in control podocytes it was declining. This trend in the p-p38 level continued to 60 min. The differences between the two groups of cells were statistically significant at 15, 30, and 60 min (Fig. 1B) . The higher and more sustained induction of p38 MAPK phosphorylation in GDI␣ KD podocytes suggests that loss of GDI␣ confers hypersensitivity to LPS-mediated injury. Next, we directly compared LPS-induced p38 phosphorylation at 15 min (corresponding to maximal induction in the control group) in control, GDI␣ KD, and KD ϩ ⌬D185 podocytes. Both GDI␣ KD and KD ϩ ⌬D185 podocytes expressed significantly higher levels of p-p38 under basal conditions compared with control podocytes (3.16-and 1.65-fold increases, respectively, P Ͻ 0.05; Fig. 1 , C and D), which were further augmented by LPS (Fig. 1D) . The results indicate that ⌬D185 is a loss of function mutation and is unable to rescue p38 activation induced by GDI␣ KD.
Rac1 contributes to LPS-mediated p38 phosphorylation in control and GDI␣ KD podocytes. We have previously demonstrated that KD of GDI␣ in podocytes leads to hyperactivation of RhoA, Rac1, and Cdc42 (13) . Following the observation Loss of endogenous Rho guanine nucleotide dissociation inhibitor-␣ (GDI␣) with and without transfection by mutant GDI␣ (⌬D185) sensitizes podocytes to LPS-induced p38 MAPK phosphorylation. Differentiated control, GDI␣ knockdown (KD), or KD with mutant GDI␣ rescue (KD ϩ ⌬D185) podocytes were exposed to LPS (25 g/ml) for the indicated times, and cell lysates were analyzed by immunoblot analysis for phosphorylated (p-)p38, p38, and GDI␣. that GDI␣ KD augments LPS-induced p38 activation, we next studied the involvement of Rho-GTPases in mediating this process using specific inhibitors of RhoA, Rac1, and Cdc42. p38 phosphorylation increased when control podocytes were treated with LPS for 15 min. In control podocytes, treatment with the Rac1 inhibitor NSC-23766 and the Cdc42 inhibitor ML-141 significantly inhibited LPS-induced p38 phosphorylation (Fig. 2, A and B) . A similar trend was observed when control podocytes were treated with the RhoA inhibitor C3 transferase, but the difference was not significant. In GDI␣ KD podocytes, LPS induced more marked p38 phosphorylation compared with control podocytes, and this was significantly inhibited by the Rac1 inhibitor but not by the RhoA or Cdc42 inhibitors (Fig. 2, A and C) . These results suggest that Rac1 contributes to LPS-mediated p38 phosphorylation in both control and GDI␣ KD podocytes. Rho-GDI␣ KD sensitizes podocytes to loss of synaptopodin and stress fibers. We next determined if the higher and more sustained induction of p-p38 in GDI␣ KD podocytes would result in a loss of synaptopodin expression and abnormal actin stress fibers. In control podocytes, treatment with LPS significantly reduced synaptopodin expression, consistent with what has been previously reported (9) (Fig. 3, A and B) . GDI␣ KD and KD ϩ ⌬D185 podocytes expressed significantly lower basal levels of synaptopodin compared with control podocytes (Fig. 3, A and B) .When GDI␣ KD or KD ϩ ⌬D185 podocytes were treated with LPS, further and significant loss of synaptopodin were observed compared with both untreated and LPS-treated control cells (Fig. 3, A and B) . By immunofluorescence, we observed similar changes in synaptopodin expression in control and GDI␣ KD cells before and after treatment with LPS (Fig. 3C) . To examine actin stress fibers and podocyte morphology, we stained control and GDI␣ KD podocytes with phalloidin. Consistent with a previous report (32) , untreated control podocytes showed well-defined transcellular stress fibers, and, when exposed to LPS, cells exhibited a loss of stress fibers and cell shape changes with more rounding and contraction (Fig. 3D) . In contrast, the majority of untreated GDI␣ KD podocytes were morphologically similar to LPStreated control cells; they showed fewer stress fibers and were more contracted. After LPS treatment, these morphological derangements were further accentuated, and ϳ90% of treated cells demonstrated severe loss of stress fibers with cortical actin accumulation and cell contraction (Fig. 3, D and E) . These results indicate that GDI␣ KD cells are more susceptible to LPS-induced synaptopodin loss and subsequent derangement in the actin cytoskeleton.
Synaptopodin degradation is mediated by p38, the proteasome, and cathepsin L in control and GDI␣ KD cells. Activation of p38 MAPK is known to regulate the ubiquitin-proteasome pathway and the corresponding turnover of proteins (7, 21, 41) . To determine if p38 activation and the ubiquitinproteasome pathway are implicated in synaptopodin loss, we exposed control and GDI␣ KD cells to LPS and determined if treatment with the p38 inhibitor SB-203580 as well as the proteasome inhibitor MG-132 was able to rescue synaptopodin protein expression. While untreated GDI␣ KD cells showed a lower expression level of synaptopodin compared with control cells, the two inhibitors significantly protected against LPSinduced synaptopodin loss in both cell lines (Fig. 4, A-C) . Since MG-132 offered partial rescue of synaptopodin loss, additional mechanisms are likely to be involved in the degra- dation of synaptopodin. In a separate set of experiments, we tested the ability of the cathepsin L inhibitor E-64 to protect against synaptopodin loss. Consistent with what has been previously reported (9) , E-64 did indeed rescue synaptopodin expression in LPS-treated control and GDI␣ KD cells (Fig. 4,  A-C ). These results demonstrate that p38, ubiquitin, and cathepsin L all contribute to LPS-induced synaptopodin degradation in control and GDI␣ KD cells. The three inhibitors were then tested for their ability to modulate basal synaptopodin levels (i.e., in the absence of LPS injury). In control podocytes, MG-132 and E-64 significantly increased synaptopodin after 8 h (Fig. 4, D and F) . In KD podocytes, all three inhibitors significantly increased the comparatively lower basal levels of synaptopodin (Fig. 4, E and F) . These results indicate that there is a basal turnover of synaptopodin mediated by the proteasome and cathepsin L. The inability of the p38 inhibitor to increase synaptopodin in control podocytes is consistent with the observation that p38 activity is low in nonstimulated control podocytes (Fig. 1) . In GDI␣ KD cells, SB-203580 significantly increased synaptopodin levels, but not to the levels observed in control cells (Fig. 4, D-F) . Therefore, p38 activation is likely not the sole mediator of synaptopodin degradation upon loss of GDI␣, but rather a contributing factor. Ubiquitination of synaptopodin is increased in GDI␣ KD podocytes in a p38-dependent manner. The experiments using the proteasome inhibitor MG-132 suggested that synaptopodin is a target for ubiquitination in podocytes. To establish if synaptopodin is ubiquitinated, protein lysates from control and GDI␣ KD cells were subjected to immunoprecipitation using an antibody to synaptopodin followed by immunoblot analysis using an antibody targeted to ubiquitin. In control podocytes, synaptopodin ubiquitination was not detectable. When cells were incubated with MG-132, a modest increase of ubiquitination was detected, indicating that a low level of synaptopodin ubiquitination and subsequent proteasomal degradation occurred in control podocytes (Fig. 5A) . In the absence of MG-132, GDI␣ KD cells did not show synaptopodin ubiquitination, similar to control cells. However, in the presence of MG-132, a marked increase of ubiquitination of synaptopodin was observed in GDI␣ KD cells, indicating that active synaptopodin ubiquitination and proteasomal degradation occurred (Fig. 5) . To establish if the ubiquitination of synaptopodin is dependent on p38, we treated both cell lines with MG-132 and the p38 inhibitor SB-203580. Treatment with both inhibitors resulted in a significant decrease in ubiquitination of synaptopodin in GDI␣ KD cells but not in control cells (Fig.  5B) . The results indicate that synaptopodin ubiquitination and proteasomal degradation are enhanced in GDI␣ KD cells and that this is dependent on p38 activity. Total cell lysates were blotted for ubiquitin before and after treatment with MG-132. Data were normalized to nontreated control cells. MG-132 caused significant increases in ubiquitin in both control (nontreated: 1.0 Ϯ 0 vs. MG-132: 2.4 Ϯ 0.42, n ϭ 3, P Ͻ 0.05) and GDI␣ KD (nontreated: 0.72 Ϯ 0.05 vs. MG-132: 1.83 Ϯ 0.3, n ϭ 3, P Ͻ 0.05) podocytes. Ubiquitin levels between control and GDI␣ KD podocytes treated with MG-132 were not significantly different. Thus, the increased ubiquitination of synaptopodin in GDI␣ KD podocytes cannot be explained by global increases in ubiquitin.
Loss of GDI␣ causes increased podocyte proliferation and decreased spreading. We (13) have previously reported that GDI␣ KD impaired the migration of podocytes. We next studied if GDI␣ KD affects other phenotypes of podocytes. Rho-GTPases such as Rac1 govern cell proliferation (5). Thus, we asked if the loss of GDI␣ would alter podocyte proliferation. By MTT assay, GDI␣ KD and KD ϩ ⌬D185 podocytes proliferated faster than control podocytes in both the absence and presence of fibronectin (Fig. 6A) . We also evaluated the effect of GDI␣ KD on podocyte spreading on the fibronectincoated surface. GDI␣ KD podocytes spread more slowly over a 24-h period than control podocytes (Fig. 6B) . In contrast, there was no difference in the number of focal adhesions per cell surface area between control and GDI␣ KD podocytes (data not shown). Loss of GDI␣ therefore alters the functional properties of podocytes. Impaired cell spreading may contribute to proteinuria, whereas impaired proliferation or adhesion to the matrix is not part of the phenotype induced by the loss of GDI␣ in podocytes.
DISCUSSION
The aim of the present study was to further understand the signaling mechanisms in podocytes that underlie the pathology caused by loss of Rho-GDI␣. We (13) have previously shown that GDI␣ loss leads to increased levels of active RhoA, Rac1, and Cdc42. Given the resulting cytoskeletal derangements and variability in time of disease onset from loss of function mutations in Rho-GDI␣, we hypothesized that this genetic abnormality is a predisposing factor to external podocyte injury. We observed higher and more sustained p38 phosphorylation in GDI␣ KD podocytes exposed to LPS, suggesting that they are more vulnerable to injury. Increased p38 activity was not rescued by transfection of GDI␣ KD podocytes with ⌬D185. We then demonstrated that Rac1 activity leads to p38 phosphorylation. When GDI␣ KD or KD ϩ ⌬D185 podocytes were exposed to LPS, they demonstrated a greater loss of synaptopodin compared with control podocytes. Consistent with the synaptopodin loss, stress fiber loss was more severe in KD podocytes compared with control podocytes. Loss of synaptopodin was rescued by inhibiting p38, the proteasome, and cathepsin L. We also report that synaptopodin ubiquitination is markedly increased in GDI␣ KD podocytes, without an observable increase in total ubiquitination levels, and that this is dependent on p38. Taken together, these experiments suggest a pathway by which heritable and environmental risk factors converge to injure podocytes.
We observed that all three prototypical Rho-GTPases (RhoA, Rac1, and Cdc42) were hyperactivated in the absence of Rho-GDI␣ in podocytes (13), whereas Gee et al. (11) observed that only Rac1 and Cdc42 were hyperactivated. Previous in vivo studies have demonstrated that Rho-GTPase activity within podocytes is tightly regulated. Podocyte-specific RhoA hyperactivation (37, 47) and inactivation (37) caused proteinuria in mice. In contrast, podocyte-specific knockout of RhoA produced no renal pathology, likely due to compensation by other Rho isoforms (30) . Similarly, deletion of Rac1 in podocytes failed to adversely affect renal function (5, 30) , whereas Rac1 hyperactivation within podocytes induced proteinuria (42) . Mice with podocyte specific deletion of Cdc42 died at 2 wk of age from kidney failure, indicating that Cdc42 is critical for podocyte development (30) . In the present study, LPS-induced p38 activation of control and GDI␣ KD podocytes was dependent on Rac1. These findings are consistent with findings in other cell types; Rac1 was shown to mediate IL-1-induced p38 activation in HeLa cells (44) and mechanical stress-induced p38 activation in smooth muscle cells (20) . We speculate that proteinuria induced by podocytespecific Rac1 hyperactivation in mice could be mediated, at least in part, by p38 activation (42) . We attempted to rescue GDI␣ KD podocytes with wild-type GDI␣. The shRNA used in the KD targeted the 3=-UTR of murine GDI␣, whereas the plasmid constructs encoding for GFP-tagged ⌬D185 and wildtype GDI␣ both lacked the 3=-UTR. The plasmid encoding GFP-tagged ⌬D185 was resistant to the shRNA, permitting high and stable expression of the mutant protein when transfected into KD cells (Figs. 1C and 3A) . However, when a similar construct was used to overexpress the wild-type sequence, we were unable to rescue KD cells because of insufficient expression of wild-type GDI␣ protein (data not shown). The reasons for this are unclear. There was sufficient wild-type GDI␣ to reverse both RhoA and Cdc42 hyperactivation; however, the reversal of Rac1 hyperactivation was partial, and we were unable to demonstrate the reversal of p38 activation. Therefore, we cannot eliminate the possibility of an off-target effect by the shRNA.
It is known that podocytes lose the expression of important proteins in experimental systems when Rho-GTPase activities are altered. For example, Rac1 activation resulted in the loss of both nephrin and podocin (42) . Additionally, both activation and inactivation of RhoA caused synaptopodin loss, whereas only activation caused nephrin loss (47) . Here, we propose a signaling cascade in podocytes (Fig. 7) that explains synap- . Proposed signaling mechanism. Rho-GTPase activation occurs after genetic (i.e., loss of function mutation in ARHGDIA) or environmental (i.e., LPS) insult. This event is followed by activation of the p38 MAPK pathway by Rac1, which activates both ubiquitin-proteosomal and cathepsin L pathways. Finally, as a result of activation of the proteasome and cathepsin L, synaptopodin is degraded, causing the loss of actin stress fibers in podocytes. topodin loss downstream of p38 activation. We propose that GDI␣ loss of function (exacerbated by environmental factors) results in hyperactivation of Rac1 and p38. Activated (phosphorylated) p38, in turn, leads to activation of the ubiquitinproteasome pathway and cathepsin L, which coordinately act to degrade synaptopodin, resulting in the derangement of the podocyte actin cytoskeleton. While we do not have direct evidence that p38 activates cathepsin L in our system, this has been previously reported; p38 activation augmented total cathepsin L levels and activity in response to collagen fragments in chondrocytes (27) .
Activated p38 can phosphorylate several downstream substrates with diverse biological functions (7) . Several studies demonstrated that protein turnover is regulated by p38. Activated p38 can induce E3 ubiquitin ligase gene expression (21, 39) . p38 can also facilitate the binding of a target protein to its E3 ubiquitin ligase by phosphorylating the target (7, 19) or by phosphorylating ubiquitin ligases directly, thereby regulating their activity (17) . With chemical inhibitors, we showed that blockade of p38 or the proteasome protects podocytes from synaptopodin loss induced by LPS. This is the first report that demonstrates that synaptopodin degradation occurs via p38 and the ubiquitin-proteasome pathway. To investigate whether synaptopodin can be ubiquitinated, we surveyed PhosphositePlus. org, an online database of posttranslational modifications. Our search for synaptopodin in the database yielded 20 ubiquitinated lysine residues identified by mass spectrometry. It remains to be determined which lysine residues (ubiquitination sites) are necessary for proteasomal degradation. Also unknown are which E3 ligase(s) interacts with synaptopodin, and whether it is regulated by p38. The possibility remains that p38 also directly phosphorylates synaptopodin, facilitating its interaction with an E3 ligase.
The present study is limited to a specific external injury, i.e., LPS. It would be interesting to know if GDI␣ KD confers sensitivity to injury by other physiologically relevant agents, such as TNF-␣ (45), transforming growth factor-␤ 1 (38) , mechanical stretch (22) , or the complement system (1, 46) . While heritable mutations in ARHGDIA are uncommon, these experiments reveal a common pathway by which heritable and environmental risk factors converge to injure podocytes, from Rac1 hyperactivation to p38 phosphorylation and synaptopodin degradation via the ubiquitin-proteasome pathway and cathepsin L. Further understanding of the precise signaling mechanisms under the control of GDI␣/Rho-GTPase in podocytes may reveal new therapeutic options for the treatment of heritable and acquired forms of NS.
